GUB-UCN2
Asset
Long-acting UCN2 analogue selectively activates CRHR2 to increase muscle mass, reduce fat mass, and improve glucose metabolism.
- Stage
- Preclinical
- Modality
- Peptide
- Target
- Lipid and ceramide metabolism
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Obesity
Preclinical, doi.org, 5 Jun 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets3
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.